Cheapest Retatrutide

Retatrutide price comparison & availability: find the cheapest Reta research peptides for sale in 10mg, 20mg & 30mg vials. Sort by cost per vial or cost per mg

Search Retatrutide prices & availability for 10mg, 20mg, 30mg and 60mg vials across 14 vendors. Sort by cost per vial, cost per mg or cost per month, and filter by COA to find the cheapest Reta research peptides for sale.

RESEARCH BUDGET PLANNER

How Much Does Retatrutide Cost per Month?

Estimate your monthly Retatrutide cost using your research inputs. Compare matching listings, check the upfront product price, and review the available vendor discount.

Estimated monthly cost spreads the product price across its calculated supply. Your checkout total may also include shipping, taxes, and applicable fees.

What Changes Your Monthly Retatrutide Cost?

The amount and frequency entered, vial size, and available vendor price all affect the estimate. Comparing the monthly figure alongside the upfront price helps you plan your research budget.

RETATRUTIDE VENDOR FINDER

Compare Retatrutide Vendors by Your Research Priorities

Answer two quick questions to narrow the Retatrutide listings by what matters to you. Review matching options, compare prices, and ask the vendor for a listing-specific COA report before choosing.

About Retatrutide

In clinical trialsAlso known as: LY3437943

Retatrutide is the investigational triple GIP/GLP-1/glucagon agonist (Eli Lilly's LY3437943), and the research peptide drawing the most interest for next-generation weight-loss studies. It ships as a lyophilized powder reconstituted with bacteriostatic water before use.[1]

What to check before you buy Retatrutide:

  • A third-party COA showing ≥99% purity by HPLC plus mass-spec confirmation of the peptide mass — important for a newer molecule where mislabeling and impure synthesis are a bigger risk.
  • A COA dated within the last 6–12 months tied to the specific batch and vial size you are ordering.
  • Accurate vial fill matching the label (a 10mg vial assaying near 10mg). Under-filled vials are a common failure mode and skew your dosing math.

A 338-person Phase 2 obesity trial (Jastreboff et al., NEJM 2023) reported mean weight reduction of approximately 24.2% at 48 weeks on the 12mg weekly arm — the largest figure published for any incretin therapy to date.[2] Parallel Phase 2 work in T2D (Rosenstock et al., Lancet 2023) showed A1C reductions of 2.0–2.2% across 4–12mg arms.[3] Phase 3 readouts from TRIUMPH-1 through TRIUMPH-4 are expected 2025–2027.

Regulatory: Not FDA-approved. Investigational only — Phase 3 TRIUMPH trials ongoing. Research-grade material sold for non-clinical use.

Read the full mechanism & research breakdown

Retatrutide: Mechanisms, Half-Life & Research Data

A skimmable deep dive into how Retatrutide works and what it is being studied for — tied back to what size to buy. Detailed debates and community notes are tucked into the expandable panels below. All citations resolve to the sources list at the bottom of this page.

How it works

Retatrutide is a single, 39-amino-acid synthetic peptide that binds three different gut-hormone receptors at once: the glucose-dependent insulinotropic polypeptide (GIP) receptor, the glucagon-like peptide-1 (GLP-1) receptor, and the glucagon receptor.[4] The GLP-1 arm slows gastric emptying, boosts glucose-dependent insulin release, and acts on hypothalamic appetite centers — the same machinery as semaglutide. The GIP arm adds a second incretin signal that appears to amplify weight loss and may improve how the body handles fat storage. The glucagon arm — absent from semaglutide and tirzepatide — is the novel piece: glucagon increases resting energy expenditure and drives lipolysis in the liver and adipose tissue.[10] A C-20 fatty-diacid sidechain binds albumin, extending the half-life to roughly 6 days and supporting once-weekly subcutaneous dosing.

Active research areas

  • Obesity (TRIUMPH-1)
    The flagship Phase 3 trial in adults with obesity but without diabetes. Investigators are measuring placebo-adjusted body-weight reduction at 80 weeks across 1–12mg arms, with the primary readout expected in 2025–2026.[1]
  • Type 2 diabetes (TRIUMPH-2)
    Phase 3 program testing whether the Phase 2 A1C reductions of 2.0–2.2% hold up against active comparators (including dulaglutide) over 52–80 weeks in adults with T2D and obesity, and whether retatrutide outperforms tirzepatide in this population.[3][6]
  • Cardiovascular outcomes (TRIUMPH-3)
    A long-running outcomes trial in adults with obesity and established cardiovascular disease. The primary endpoint is a composite of cardiovascular death, non-fatal myocardial infarction, and non-fatal stroke — testing whether retatrutide reproduces the cardiovascular benefit semaglutide showed in SELECT.[7]
  • Metabolic dysfunction-associated steatohepatitis (MASH)
    A Phase 2a trial reported that retatrutide reduced liver fat by roughly 80–86% at 24 weeks at the 8mg and 12mg doses — the largest hepatic-fat reduction reported for any incretin therapy to date.[5] Phase 3 MASH work is being scoped on the back of this signal.
  • Heart failure with preserved ejection fraction (HFpEF)
    TRIUMPH-HF is enrolling adults with obesity and HFpEF to measure whether the weight, metabolic, and hepatic-fat improvements translate into reduced heart-failure hospitalisations and better exercise tolerance.[9]
  • Knee osteoarthritis with obesity (TRIUMPH-4)
    TRIUMPH-4 is asking whether the large weight reductions produce measurable improvements in WOMAC pain and function scores in patients with obesity-driven knee OA.[8]
  • Obstructive sleep apnea (OSA)
    No dedicated retatrutide OSA Phase 3 trial is registered as of mid-2026, but OSA is an active question for the incretin class: tirzepatide reduced the apnea–hypopnea index by roughly 50–60% in SURMOUNT-OSA, with the benefit tracking weight loss.[13] Because retatrutide produces larger weight reductions than tirzepatide in Phase 2,[2] a comparable or larger OSA effect is plausible — but this has not been demonstrated directly and would require a dedicated trial to confirm.
Open questions & leading hypotheses (3)
  • Hypothesis: Adding glucagon-receptor activity is what makes retatrutide produce larger weight loss than tirzepatide.
    Evidence: Phase 2 obesity data reported ~24.2% mean weight reduction at 48 weeks on the 12mg arm — meaningfully larger than the ~20.9% SURMOUNT-1 figure for tirzepatide at 72 weeks.[2] The mechanistic case is that glucagon raises resting energy expenditure and drives hepatic lipolysis.[10] Counter-evidence: cross-trial comparisons are unreliable, glucagon agonism has historically been associated with hyperglycemia and lean-mass loss, and the relative contributions of GIP, GLP-1, and glucagon to the weight-loss signal have not yet been isolated in head-to-head receptor-blockade studies.
  • Hypothesis: Retatrutide will cause more lean-mass loss than pure GLP-1 or dual GIP/GLP-1 agonists because of its glucagon arm.
    Evidence: Glucagon historically drives protein catabolism in the liver, raising the hypothesis that triple agonism will tilt the lean-to-fat-mass ratio of weight loss unfavourably.[10] Counter-evidence: Phase 2 DXA substudies of retatrutide have not yet been published in a form that resolves this; the existing all-cause weight figures do not distinguish fat from lean tissue, and the question will only be answered cleanly with Phase 3 body-composition data.
  • Hypothesis: The hepatic-fat reductions seen in Phase 2 will translate into MASH resolution and fibrosis improvement in Phase 3.
    Evidence: The Phase 2a MASLD trial reported ~80–86% liver-fat reduction at 24 weeks, and weight loss of that magnitude is itself associated with MASH benefit.[5] Counter-evidence: fat reduction does not always reduce fibrosis in MASH, and no biopsy-confirmed fibrosis-improvement data with retatrutide has been published as of mid-2026.
What community users report

Anecdotal — not controlled-trial evidence

Across r/Retatrutide and r/PeptideAdmin, users running unsanctioned research-grade protocols most often report rapid appetite suppression beginning within the first week, weekly weight loss meaningfully larger than what they previously experienced on semaglutide or tirzepatide, and pronounced gastrointestinal side effects (nausea, constipation, sulphur burps) that frequently force slower titration than the trial protocols use.[11][12] Several threads describe people stopping due to fatigue or "feeling cold" — both of which are consistent with the increased basal energy expenditure that glucagon-receptor agonism would predict, but neither is a controlled observation. **These reports are anecdotal and have not been validated in controlled trials.** They are useful for understanding what people who have already decided to experiment are saying, but they do not establish that retatrutide is safe or effective for any indication outside the ongoing Phase 3 program.

Sources & references (13)

Peer-reviewed literature, FDA documents, and trial registrations cited above. Vendor pricing, COA data, and live calculator statistics shown elsewhere on this page are sourced from the WPA database independently of this list.

  1. [1]ClinicalTrials.gov: TRIUMPH-1 (NCT05929066) — Phase 3 retatrutide in adults with obesity link
  2. [2]Jastreboff AM et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity — Phase 2 Trial. NEJM 2023;389:514–526. · PMID: 37366315 link
  3. [3]Rosenstock J et al. Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial. Lancet 2023;402:529–544. · PMID: 37385280 link
  4. [4]Coskun T et al. LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept. Cell Metab 2022;34:1234–1247.e9. · PMID: 35985340 link
  5. [5]Sanyal AJ et al. Triple Hormone Receptor Agonist Retatrutide for Metabolic Dysfunction-Associated Steatotic Liver Disease — a randomized phase 2a trial. Nature Medicine 2024;30:2037–2048. · PMID: 38858524 link
  6. [6]ClinicalTrials.gov: TRIUMPH-2 (NCT05929079) — Phase 3 retatrutide in adults with obesity and type 2 diabetes link
  7. [7]ClinicalTrials.gov: TRIUMPH-3 (NCT05882045) — Cardiovascular outcomes with retatrutide in obesity and established cardiovascular disease link
  8. [8]ClinicalTrials.gov: TRIUMPH-4 (NCT06322199) — Retatrutide in adults with knee osteoarthritis and obesity link
  9. [9]ClinicalTrials.gov: TRIUMPH-HF (NCT06560853) — Retatrutide in heart failure with preserved ejection fraction and obesity link
  10. [10]Müller TD et al. The new biology and pharmacology of glucagon. Physiol Rev 2017;97:721–766 — review of glucagon-receptor contribution to energy expenditure and lean-mass loss in dual/triple agonists. · PMID: 28275048 link
  11. [11]Community report — r/Retatrutide weekly experience threads (subreddit), accessed May 2026. link
  12. [12]Community report — r/PeptideAdmin retatrutide protocol discussions (subreddit), accessed May 2026. link
  13. [13]Malhotra A et al. Tirzepatide for the treatment of obstructive sleep apnea and obesity (SURMOUNT-OSA). NEJM 2024;391:1193–1205 — cross-class incretin precedent for OSA benefit driven by weight loss. · PMID: 38912654 link

What Retatrutide Costs Right Now

WPA currently tracks Retatrutide from 12 distinct vendors across 53 separate Retatrutide listings. In-stock Retatrutide vials run from $35.10 to $1393.20 — a 39.7x spread for the same compound. Ameano Peptides holds the lowest sticker price at $35.10. Normalized to milligrams, Retatrutide costs $1.27/mg to $13.46/mg on this page. The best per-milligram value is the listed 100 mg purchase quantity from Southern Aminos.

Retatrutide is stocked in 15 sizes: 100 mg listed quantity; vial count not recorded; 10 mg listed quantity; vial count not recorded; 120 mg listed quantity; vial count not recorded; 12 mg listed quantity; vial count not recorded; 200 mg listed quantity; vial count not recorded; 20 mg listed quantity; vial count not recorded; 240 mg listed quantity; vial count not recorded; 24 mg listed quantity; vial count not recorded; 30 mg listed quantity; vial count not recorded; 300 mg listed quantity; vial count not recorded; 480 mg listed quantity; vial count not recorded; 48 mg listed quantity; vial count not recorded; 50 mg listed quantity; vial count not recorded; 60 mg listed quantity; vial count not recorded; 6 mg listed quantity; vial count not recorded. Because vials of different strengths rarely scale linearly in price, the per-milligram column is the only fair way to rank them.

Ranked by true cost per milligram, the Retatrutide listings WPA tracks are: Southern Aminos — 100mg at $126.65 ($1.27/mg), COA purity 99.74%; Modified Aminos — 100mg at $251.99 ($2.52/mg), COA purity 99.80%; Southern Aminos — 60mg at $152.15 ($2.54/mg), COA purity 99.74%; Southern Aminos — 30mg at $79.90 ($2.66/mg), COA purity 99.61%; EZ Peptides — 240mg at $664.20 ($2.77/mg), COA purity 99.56%.

Retatrutide COA Coverage Across Tracked Vendors

45 of the 53 tracked Retatrutide listings (85%) are marked as having COA availability in WPA's listing data; this marker is not independent verification. A purity value is recorded for 45 listings; purity alone does not establish identity or independent testing. The recorded purity values range from 98.38% to 99.97%. 38 listings record more Retatrutide in the vial than the label claims; check the vendor's report and batch before drawing conclusions. The latest COA date recorded in WPA's listing data is 11/26.

To assess a COA, inspect the actual report for the independent lab, test date, and a batch and vial size matching the Retatrutide offer. WPA's listing fields do not establish that a report was independently verified.

Retatrutide Calculator Input Observations

In lifetime Retatrutide calculator inputs, 2mg is the most frequent entered amount (20,020 of 98,919 runs). Separately, Weekly (1x/wk) is the most frequent overall cadence (12,571 of 16,937 lifetime frequency responses, across entered amounts). Among lifetime frequency responses with amounts within ±8% of 2mg, Weekly (1x/wk) is most frequent (2,856 of 3,807 responses). Calculator runs and frequency responses are different populations, not unique people or confirmed administration. Separate modal inputs do not establish a most-common joint protocol, a recommendation, or a cycle length. As nominal quantity arithmetic only, 480 mg of listed product divided by 2 mg gives roughly 240 portions before preparation losses. This does not establish vial count, stability after preparation, or cycle length.

Retatrutide Discount Codes

53 of the 53 tracked Retatrutide listings carry a WPA researcher discount code. The largest live discount is 50% off. Every price and per-milligram figure on this page is the post-discount number, so you are never comparing a discounted listing against an undiscounted one. Codes change and some exclude sale items or carry order minimums.

About Retatrutide

Retatrutide is the investigational triple GIP/GLP-1/glucagon agonist (Eli Lilly's LY3437943), and the research peptide drawing the most interest for next-generation weight-loss studies. It ships as a lyophilized powder reconstituted with bacteriostatic water before use.

Retatrutide is tracked under the Weight Loss category on WPA. Its reported half-life is ~6 days. Calculator inputs do not establish why a cadence was selected or validate a protocol. Not FDA-approved.

How to Read the Retatrutide Comparison

  • Price per milligram — Every Retatrutide listing is normalized to $1.27/mg-style unit pricing, so a small cheap vial cannot hide a worse real cost than a larger one.
  • COA metadata and purity — 45 Retatrutide listings are marked for COA availability, and 45 have a recorded purity value. These fields do not independently verify a report.
  • Vials sizes — The Retatrutide comparison includes 6mg, 10mg, 12mg, 20mg, 24mg, 30mg, 48mg, 50mg, 60mg, 100mg, 120mg, 200mg, 240mg, 300mg, and 480mg listed purchase quantities. Check package composition separately.
  • Stock status — Live in-stock state for each Retatrutide listing, refreshed on a recurring basis.

Frequently Asked Questions: Retatrutide

Is it legal and safe to buy Retatrutide for research?

In the US, Retatrutide is sold strictly as a research chemical — legal to buy for laboratory research but not approved for human use. It is an investigational triple GLP-1/GIP/glucagon receptor agonist with no approved human form anywhere in the world. The real variable isn't legality, it's quality: unverified suppliers can ship underdosed, impure, or mislabeled material. WPA records COA-related listing fields where supplied, but does not independently verify every report. Inspect the actual batch report and its laboratory, identity testing, and date before drawing conclusions. Right now that screen covers 53 Retatrutide listings from 12 vendors.

How do I verify a Retatrutide COA so I'm not getting an underdosed vial?

A Certificate of Analysis (COA) may report tests for a specific Retatrutide batch. Check that the report identifies the compound (actually retatrutide, not semaglutide, tirzepatide, or an underdosed mix), names the laboratory, describes the test method and result, and matches the offered batch and date. A recorded purity value or COA-availability flag in WPA's listing data is not independent verification. Open the vendor listing and inspect the actual report before drawing conclusions. For Retatrutide specifically, 45 of 53 tracked listings (85%) are marked as having COA availability in WPA's listing data; that marker is not independent verification. A purity value is separately recorded for 45 listings; purity alone does not establish identity or independent testing. The latest COA date recorded in the listing data is 11/26.

Which Retatrutide vendor should I pick?

There's no single "best" Retatrutide vendor — it depends on what you weigh most. WPA ranks tracked listings using recorded purity and date fields where available, visitor click activity, price, stock status, and discount data; this ranking is not independent verification of a report. Because retatrutide is newer and pricier than other GLP-1s, COA recency and assayed purity carry extra weight — you don't want to overpay for underfilled vials. 12 vendors currently carry Retatrutide, and Southern Aminos holds the best true value at $1.27/mg on the 100 mg listed purchase quantity. Review the actual report and confirm its batch details before making a decision.

How much does Retatrutide cost — and how do I know I'm not overpaying?

Judge Retatrutide by true price per milligram, not the sticker price on one vial — a cheap small vial often costs more per mg than a larger one. Retatrutide commonly ships in 10, 15, and 20 mg vials, and the larger sizes usually win on $/mg because a full titration needs the extra peptide anyway. Tracked Retatrutide listings currently run $1.27/mg to $13.46/mg across 6mg, 10mg, 12mg, 20mg, 24mg, 30mg, 48mg, 50mg, 60mg, 100mg, 120mg, 200mg, 240mg, 300mg, 480mg listed purchase quantities (not necessarily single vials). WPA normalizes tracked listings to $/mg, and the live cost-per-month card estimates your spend at the most common dose. The one catch: the lowest $/mg sometimes means buying a bigger vial than your cycle needs.

How much Retatrutide do I need for one full cycle?

In lifetime Retatrutide calculator inputs, 2mg is the most frequent entered amount (20,020 of 98,919 runs). Separately, Weekly (1x/wk) is the most frequent overall cadence (12,571 of 16,937 lifetime frequency responses, across entered amounts). Among lifetime frequency responses with amounts within ±8% of 2mg, Weekly (1x/wk) is most frequent (2,856 of 3,807 responses). Calculator runs and frequency responses are different populations, not unique people or confirmed administration. Separate modal inputs do not establish a most-common joint protocol, a recommendation, or a cycle length. Dividing the listed 480 mg purchase quantity by 2 mg gives roughly 240 nominal portions before preparation losses; vial count and stability after preparation are separate questions. A cycle requires an independently chosen amount, cadence and time horizon; calculator observations do not supply those decisions. Compare nominal package quantities and model your own selections in the cost card.

Are discount codes available for Retatrutide?

Participating Retatrutide vendors may offer WPA researcher discount codes. Codes can change, exclude sale items or carry order minimums. 53 of the 53 tracked Retatrutide listings carry a code right now, the largest worth 50% off. Each listing shows the recorded code and discounted price where available; confirm the actual package and checkout terms with the vendor.

Lowest priced Retatrutide peptide for sale?

To surface the lowest priced Retatrutide for sale, WPA continuously compares 14 USA suppliers and 956 "for research" products, ranking every verified Retatrutide listing by true cost so the cheapest vials rise to the top. The lowest priced single Retatrutide vial currently starts at $35.10. We currently track 53 Retatrutide products in our system. Pricing is generally refreshed weekly as vendors update stock, prices, and discount codes.

Compare Retatrutide Vendors: Purity, COAs, and Total Cost

The best Retatrutide vendor for your research depends on more than the listed price. Compare suppliers using the same vial size and format, review the Certificate of Analysis (COA) for the relevant batch, and confirm the full checkout cost.

What to Check on a Retatrutide COA

Batch and report details

Match the report’s batch or lot number to the product being offered. Check the laboratory name, report identifier, and test date so you know which sample the results describe.

Compound identity

Look for an identity result identifying Retatrutide and the method used. A purity percentage alone does not establish the identity of the tested compound.

Reported purity

Compare the reported purity percentage alongside the analytical method. For a useful Retatrutide purity comparison, check that the reports measure comparable attributes rather than judging by the largest percentage alone.

Measured peptide quantity

Where quantitative testing is available, compare the reported milligrams per vial with the labeled amount. Confirm the units and whether the result describes a whole vial or a prepared sample.

Why Purity and Quantity Both Matter

Purity and peptide quantity answer different questions. A report showing 99% purity does not, by itself, establish that a vial contains its labeled milligram amount.

When comparing Retatrutide suppliers, read both results where available. Similar purity percentages can accompany different measured quantities. COA results describe the tested sample; they do not establish the contents of every vial shipped.

Compare the Total Retatrutide Cost at Checkout

Start with the listed price after the applicable discount, then check shipping, taxes, and any additional fees. Confirm that the discount code applies to your selected product and whether free shipping requires a minimum order.

Review stock availability, dispatch timing, and the vendor’s policy for lost or damaged shipments before making your selection.

Compare the same product, review its testing documentation, and confirm the final cost to find the option that fits your research requirements.